Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TA-7284 (SGLT2 inhibitor) in type 2 diabetes mellitus
NCT01022112Phase 2Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Nov 2009
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of canagliflozin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Mitsubishi Tanabe Pharma. Primary endpoint: Hemoglobin A1c at 12 weeks. Started Nov 2009; status: completed.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01022112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01022112.